Shan Ahmed Khan

Shan Ahmed Khan is a senior markets reporter at TS2.tech, specializing in stocks, technology and macroeconomic trends. A graduate of the Lahore University of Management Sciences (LUMS), he previously worked in investment research and market analysis. His coverage helps readers understand the key developments influencing global financial markets and emerging industries.

PLS Group stock hits a 52-week high as China lithium surges — what investors watch next

PLS Group Limited shares climbed 1.9% to close Tuesday at A$4.86, having peaked at A$4.92 earlier. That puts the stock near the top of its 52-week range, valuing the miner around A$15.7 billion.

13 January 2026

ASX:PLS·China Economy·Stock Market

NAB shares end higher as rate-hike chatter flares — what investors watch next

Shares of National Australia Bank Limited climbed 1.85% to close at A$42.39 on Tuesday, marking their second consecutive day of gains and outperforming the wider market.

13 January 2026

ASX:NAB·Interest Rates·Stock Market

CBA stock rises after new wage data — what to watch before Commonwealth Bank’s Feb results

Shares of Commonwealth Bank of Australia ended Tuesday up 0.8%, buoyed by new labour-market data that continue to fuel discussion around interest rates.

13 January 2026

ASX:ANZ.AX·ASX:CBA.AX·ASX:NAB.AX·ASX:WBC.AX·Earnings Reports·Stock Market

Lynas Rare Earths stock rises on CEO exit plan — what ASX:LYC investors watch next

Lynas Rare Earths Ltd shares closed up 2.5% at A$15.15 on Tuesday after CEO Amanda Lacaze announced she plans to retire following 12 years in the role. The board has launched a search for her successor, with Lacaze set to remain until the end of the financial year. Chair John Humphrey highlighted that the company’s market value has surged from around A$400 million in 2014 to nearly A$15 billion.

13 January 2026

ASX Updates·ASX:LYC·Stock Market

Northern Star stock jumps 3.6% as gold holds near record highs — here’s what traders watch next

Northern Star Resources Ltd saw its shares climb 3.6% on Tuesday, closing at A$26.35. The gold miner ranked among the most active large caps as buyers stepped back in. According to an ASX report, turnover hit around A$133 million.

13 January 2026

ASX:NST·Gold·Stock Market

Fortescue stock rebounds as iron ore firms, filings flag incentive-plan moves

Fortescue Ltd shares closed 0.9% higher at A$22.60 on Tuesday, recovering some ground after slipping the day before and maintaining its spot amid a volatile January.

13 January 2026

ASX:FMG

BHP stock rises as it stays out of the Rio-Glencore chase — what investors watch next

BHP Group’s U.S.-listed shares climbed 1.7% to $62.80 on Monday as investors digested reports that the miner isn’t planning a rival bid for Glencore. Instead, BHP appears set to wait on Rio Tinto’s takeover discussions, according to two sources familiar with the situation. Those sources also said BHP doesn’t see Glencore’s coal and trading units as a good strategic fit. BHP declined to comment.

13 January 2026

Mining Industry·NYSE:BHP·NYSE:FCX·NYSE:RIO·Stock Market

Capital One stock drops on Trump’s 10% credit-card rate cap talk as $425 million depositor settlement advances

Shares of Capital One Financial dropped 6.4% to $233.20 in after-hours trading Monday, dragged down by a widespread selloff among credit-card lenders. The slide followed President Donald Trump's call to impose a 10% cap on credit-card interest rates for one year.

12 January 2026

NYSE:AXP·NYSE:BFH·NYSE:COF·NYSE:MA·NYSE:SYF·NYSE:V·Stock Market

Alnylam stock slides after “Alnylam 2030” plan, Amvuttra Q4 sales come up short

Alnylam Pharmaceuticals shares dropped in late Monday trading after the RNA interference drugmaker unveiled a new five-year plan and provided early 2026 sales guidance, along with preliminary figures for 2025. The stock slipped roughly 6.7% to $370.91.

12 January 2026

Earnings Reports·NASDAQ:ALNY·Pharmaceuticals·Stock Market

iRhythm (IRTC) stock drops after JPM update points to $880 million 2026 revenue

Shares of iRhythm Technologies Inc fell 5.6% to $169.30 in late Monday trading following a preliminary business update at the J.P. Morgan Healthcare Conference. The stock fluctuated between $157.34 and $179.82, with roughly 1.35 million shares changing hands.

12 January 2026

Earnings Reports·NASDAQ:IRTC·Stock Market

Why Pattern Group (PTRN) stock slid nearly 8% — and what investors watch next

Pattern Group Inc shares slipped 7.8% to $13.39 in late Nasdaq action on Monday, fluctuating between $13.20 and $14.58 throughout the session. Trading volume hit roughly 1.4 million shares.

12 January 2026

NASDAQ:PTRN.O·Stock Market

Urban Outfitters stock slides despite “record” holiday sales — what spooked URBN shares

Urban Outfitters shares dropped roughly 12% Monday following a 9% increase in holiday sales—proof that even solid results can disappoint when expectations are steep. The stock hit an intraday low of $70.27 before recovering slightly to $71.49.

12 January 2026

Earnings Reports·NASDAQ:URBN·Stock Market

CompoSecure stock drops 8% as Husky deal closes; GPGI ticker switch set for Jan. 23

CompoSecure, Inc. shares dropped roughly 8% Monday after the metal payment-card maker announced it finalized its business combination with Husky Technologies and will rebrand as GPGI. The stock slid $1.79 to $20.39 in afternoon trading in New York, fluctuating between $20.15 and $22.15 earlier. The company said its shares will start trading under the new ticker “GPGI” on Jan. 23.

12 January 2026

NASDAQ:CMPO·Stock Market

Dave Inc stock drops nearly 9% as fintech lenders slide; CPI test looms for DAVE

Shares of Dave Inc dropped 8.8% to $218.29 in late-afternoon trading Monday, after earlier fluctuating between $212.10 and $247.74. The fintech’s stock had closed Friday at $239.35, with roughly 1.1 million shares changing hands by mid-afternoon, according to market data.

12 January 2026

Fintech·NASDAQ:DAVE·Stock Market

Arcutis Biotherapeutics stock slides after 2026 ZORYVE sales outlook; June FDA deadline in focus

Shares of Arcutis Biotherapeutics dropped 8.7% on Monday, slipping $2.46 to $25.76, following the company’s update on its 2026 priorities. The dermatology drugmaker set a $455 million to $470 million target for net product sales in its ZORYVE franchise. The stock hit a session low of $25.51 during trading.

12 January 2026

NASDAQ:ARQT·Pharmaceuticals·Stock Market

Caris Life Sciences (CAI) stock drops on preliminary 2025 results, Everlywell cancer-screening deal

Caris Life Sciences shares dropped roughly 8.5% to $26.08 in afternoon trading, after fluctuating between $25.35 and $29.77 earlier today.

12 January 2026

Biotechnology·NASDAQ:CAI·Stock Market

HealthEquity stock slides nearly 10% after 2027 outlook; JPM conference is next test

Shares of HealthEquity dropped roughly 10% in Monday afternoon trading following the benefits administrator’s cautious initial fiscal 2027 outlook. The stock last traded down $9.53 at $84.62, hitting a session low around $84.51.

12 January 2026

Earnings Reports·NASDAQ:HQY·Stock Market

Synchrony Financial stock slides on Trump’s 10% credit-card rate cap pitch — what investors watch next

Shares of Synchrony Financial dropped sharply on Monday, tumbling 8.2% to $79.76 in afternoon trading. The slide followed President Donald Trump’s push for a one-year cap on credit-card interest rates at 10%, a move investors warn could severely tighten card lending profits.

12 January 2026

NYSE:SYF·Stock Market

Mesoblast (MESO) stock drops 11% as traders digest insider buy and Ryoncil sales backdrop

Mesoblast Ltd’s shares on the U.S. market dropped roughly 11% Monday, sliding to $18.64 in afternoon trading after hitting $20.14 earlier. The Australian biotech’s stock has seen sharp swings since it started highlighting early commercial progress for its main cell therapy.

12 January 2026

NASDAQ:MESO

Summit Therapeutics stock tumbles as FDA filing for ivonescimab hits tape, GSK trial tie-up follows

Shares of Summit Therapeutics Inc dropped roughly 11% to $17.46 Monday afternoon, after fluctuating between $20.30 and $16.51. The move came following the company’s announcement that it filed a U.S. biologics license application for its lung cancer drug ivonescimab.

12 January 2026

Healthcare News·NASDAQ:SMMT

Previous 1 … 271 272 273 274 275 … 610 Next

#1 STRONG BUY

Xylem

NYSE: XYL 95 / 100

#2 BUY

AerCap

NYSE: AER 93 / 100

#3 BUY ON WEAKNESS

Visa

NYSE: V 90 / 100

#4 TACTICAL BUY

Chevron

NYSE: CVX 87 / 100

#5 ACCUMULATE

UPS

NYSE: UPS 84 / 100

View full portfolio

Shan Ahmed Khan

PLS Group stock hits a 52-week high as China lithium surges — what investors watch next

NAB shares end higher as rate-hike chatter flares — what investors watch next

CBA stock rises after new wage data — what to watch before Commonwealth Bank’s Feb results

Lynas Rare Earths stock rises on CEO exit plan — what ASX:LYC investors watch next

Northern Star stock jumps 3.6% as gold holds near record highs — here’s what traders watch next

Fortescue stock rebounds as iron ore firms, filings flag incentive-plan moves

BHP stock rises as it stays out of the Rio-Glencore chase — what investors watch next

Capital One stock drops on Trump’s 10% credit-card rate cap talk as $425 million depositor settlement advances

Alnylam stock slides after “Alnylam 2030” plan, Amvuttra Q4 sales come up short

iRhythm (IRTC) stock drops after JPM update points to $880 million 2026 revenue

Why Pattern Group (PTRN) stock slid nearly 8% — and what investors watch next

Urban Outfitters stock slides despite “record” holiday sales — what spooked URBN shares

CompoSecure stock drops 8% as Husky deal closes; GPGI ticker switch set for Jan. 23

Dave Inc stock drops nearly 9% as fintech lenders slide; CPI test looms for DAVE

Arcutis Biotherapeutics stock slides after 2026 ZORYVE sales outlook; June FDA deadline in focus

Caris Life Sciences (CAI) stock drops on preliminary 2025 results, Everlywell cancer-screening deal

HealthEquity stock slides nearly 10% after 2027 outlook; JPM conference is next test

Synchrony Financial stock slides on Trump’s 10% credit-card rate cap pitch — what investors watch next

Mesoblast (MESO) stock drops 11% as traders digest insider buy and Ryoncil sales backdrop

Summit Therapeutics stock tumbles as FDA filing for ivonescimab hits tape, GSK trial tie-up follows

TechStock² Updates

Bristol Myers Squibb (NYSE:BMY) faces valuation test Monday as report of potential partnership emerges

American Airlines Group Inc. (NASDAQ:AAL): $1.6 Billion Fuel Reset Equals 16% of Market Value

Alphabet (NASDAQ:GOOGL) Eyes $119 Billion AI Outlay as Rebound Put to the Test

AstraZeneca (NYSE:AZN)–Bristol Myers Squibb (NYSE:BMY): Potential $455 Billion Tie-Up Raises Questions Over Deal Value

Rivian Shares Fall as R2 Growth Requires Minimum 74% Increase in Deliveries

Top Stock Picks

Xylem

AerCap

Visa

Chevron

UPS

Live updates

Investment Disclaimer